Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials.

Okines, A F C; Gonzalez de Castro, D; Cunningham, D; Chau, I; Langley, R E; Thompson, L C; Stenning, S P; Saffery, C; Barbachano, Y; Coxon, F; Middleton, G; Ferry, D; Crosby, T; Madhusudan, S; Wadsley, J; Waters, J; Hall, M; Swinson, D; Robinson, A; Smith, D; Reis-Filho, J S; Waddell, T S; Puckey, L; Hulkki Wilson, S; Eltahir, Z; Band, M; Wotherspoon, A

Okines, A F C; Gonzalez de Castro, D; Cunningham, D; Chau, I; Langley, R E; Thompson, L C; Stenning, S P; Saffery, C; Barbachano, Y; Coxon, F; Middleton, G; Ferry, D; Crosby, T; Madhusudan, S; Wadsley, J; Waters, J; Hall, M; Swinson, D; Robinson, A; Smith, D; Reis-Filho, J S; Waddell, T S; Puckey, L; Hulkki Wilson, S; Eltahir, Z; Band, M; Wotherspoon, A.

Affiliation

Okines AF; The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
Gonzalez de Castro D; The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
Cunningham D; The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom. Electronic address: david.cunningham@rmh.nhs.uk.
Chau I; The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
Langley RE; Medical Research Council Clinical Trials Unit, London, United Kingdom.
Thompson LC; Medical Research Council Clinical Trials Unit, London, United Kingdom.
Stenning SP; Medical Research Council Clinical Trials Unit, London, United Kingdom.
Saffery C; The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
Barbachano Y; The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
Coxon F; Northern Centre for Cancer Care, Newcastle, United Kingdom.
Middleton G; Royal Surrey County Hospital, Guildford, United Kingdom.
Ferry D; Russells Hall Hospital, Dudley, United Kingdom.
Crosby T; Velindre Cancer Centre, Cardiff, United Kingdom.
Madhusudan S; Nottingham University Hospitals, United Kingdom.
Wadsley J; Weston Park Hospital, Sheffield, United Kingdom.
Waters J; Kent Oncology Centre, Maidstone, United Kingdom.
Hall M; Heatherwood and Wexham Park Hospital, United Kingdom.
Swinson D; St. James' Hospital, Leeds, United Kingdom.
Robinson A; Conquest Hospital, United Kingdom.
Smith D; Clatterbridge Centre for Oncology, Wirral, United Kingdom.
Reis-Filho JS; The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Waddell TS; The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
Puckey L; The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
Hulkki Wilson S; The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
Eltahir Z; The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
Band M; The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
Wotherspoon A; The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.

Eur J Cancer ; 49(9): 2116-25, 2013 Jun.

Article de En | MEDLINE | ID: mdl-23481512

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de l'estomac / Tumeurs de l'oesophage / Adénocarcinome / Mutation Type d'étude: Clinical_trials / Prognostic_studies Limites: Humans Langue: En Journal: Eur J Cancer Année: 2013 Type de document: Article Pays d'affiliation: Royaume-Uni Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google